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Early diagnosis of primary immunodeficiency disorders (PID) is vital and allows
directed treatment, especially in syndromes with severe or profound combined
immunodeficiency. In PID patients with perinatal CMV or other opportunistic, invasive
infections (e.g., Pneumocystis or Aspergillus), multi-organ morbidity may already arise
within the first months of life, before hematopoietic stem cell transplantation (HSCT)
or gene therapy can be undertaken, compromising the definitive treatment and
outcome. Deficiency of Wiskott-Aldrich syndrome (WAS) protein-interacting protein
(WIP deficiency) causes an autosomal recessive, WAS-like syndrome with early-onset
combined immunodeficiency that has been described in three pedigrees to date.
While WAS typically includes combined immunodeficiency, microthrombocytopenia, and
eczema, the clinical and laboratory phenotypes of WIP-deficient patients–including
lymphocyte subsets, platelets, lymphocyte proliferation in vitro, and IgE—varied widely
and did not entirely recapitulate WAS, impeding early diagnosis in the reported
patients. To elucidate the phenotype of WIP deficiency, we provide a comprehensive
synopsis of clinical and laboratory features of all hitherto-described patients (n = 6)
and WIP negative mice. Furthermore, we summarize the treatment modalities and
outcomes of these patients and review in detail the course of one of them who
was successfully treated with serial, unconditioned, maternal, HLA-identical donor
lymphocyte infusions (DLI) against life-threatening, invasive CMV infection, followed by a
TCRαβ/CD19-depleted, treosulfan/melphalan-conditioned, peripheral blood HSCT and
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repetitive, secondary-prophylactic, CMV-specific DLI with 1-year post-HSCT follow-up.
This strategy could be useful in other patients with substantial premorbidity, considered
“too bad to transplant,” who have an HLA-identical family donor, to eliminate infections
and bridge until definitive treatment.
Keywords: Wiskott-Aldrich syndrome protein-interacting protein (WIP), primary immunodeficiency (PID), Wiskott-
Aldrich syndrome (WAS), hematopoietic stem cell transplantation (HSCT), donor lymphocyte infusions (DLI),
combined immunodeficiency (CID) with syndromic features, inborn errors of immunity
INTRODUCTION
Wiskott-Aldrich syndrome (WAS) is an X-linked, classical
combined immunodeficiency with syndromic features,
defined by a clinical trias of immunodeficiency, eczema,
and microthrombocytopenia that bears a risk of autoimmunity
and lymphoma (1–5). Allogeneic hematopoietic stem cell
transplantation (HSCT) is the treatment of choice, if a suitable
donor is available. Deficiency ofWAS protein-interacting protein
(WIP) is a recessive disorder that leads to premature degradation
of WAS protein (WASP) and thus highly resembles WAS.
However, the clinical presentation and courses of previously
reported patients with WIP deficiency were more heterogeneous
than those of WAS patients (6–8), especially with regards to very
early onset of severe, life-threatening immunodeficiency. The
conditioning pretreatment before HSCT of patients with WAS
and other profound combined immunodeficiencies includes
strongly immunosuppressive chemotherapy, and the outcome
depends on the degree of preexisting and acquired invasive
infections until engraftment enables the generation of an intact
immune system.
FUNCTIONAL ASPECTS OF WIP OR WASP
DEFICIENCY
WASP is present in the cytoplasm of hematopoietic cell lineages
in an auto-inhibited, inactive form that is stabilized in a
chaperone-like fashion by WIP binding (9). Upon activation
by cell division cycle 2 (CDC42), a Rho family GTPase,
activated by a variety of transmembrane receptors, or by proline-
serine-threonine phosphatase-interacting protein 1 (PSTPIP1),
and phosphatidylinositol-4,5-biphosphate (PIP2), the inhibitory,
intramolecular, interaction is released, and actin polymerization
is initiated [reviewed in Cotta-de-Almeida et al. (10)]. Besides
the WASP-stabilizing function of WIP, it was shown to facilitate
WASP activation by recruiting WASP to the immunological
synapse upon activation of the T cell receptor and by enhancing
CDC42-dependent activation (11). Actin polymerization is
necessary for the immunological synapse formation, its stability,
intracellular signaling, cytokine secretion, cellular migration,
and lytic granule polarization, but there are also other actin-
independent effects of WASP such as activity as transcription
factor for T-bet and as anti-apoptotic survival factor (10). In
Abbreviations: WASP, Wiskott-Aldrich syndrome protein; WIP, WASP
interacting protein; PID, primary immunodeficiency; NGS, next generation
sequencing; DLI, donor lymphocyte infusions; CMV, cytomegalovirus.
addition to the T cell pathology notoriously associated with
WAS, many of these functional defects also affect B cells [such
as migration toward a chemokine gradient (8)] and NK cells
(12, 13), and there is evidence frommurine studies, that WIP has
WASP-independent effects on B cell function, being a regulator
of CD19 activation and PI3K/Akt signaling in B cells (14).
Active WASP is stabilized by tyrosine phosphorylation, and its
activity is counter-balanced by ubiquitin-dependent proteasomal
degradation [reviewed in Cotta-de-Almeida et al. (10)].
SYNOPSIS OF SIX WIP-DEFICIENT
PATIENTS FROM THREE PEDIGREES
The first description of a WIP-deficient patient was from a girl
fromMorocco in 2012, who had been diagnosed and successfully
transplanted with cord-blood-derived stem cells in Brescia, Italy,
at 4.5 months and followed-up at that time for 16 months
(6) (Table 1, pedigree A). Her appearance largely resembled
WAS, but at that time, except for rare cases of imbalanced
X chromosomal inactivation (15, 16), WAS in females or a
recessive form was unknown or genetically unresolved (17).
Results of immunological analyses, including the T and NK
cell functions and an absence of WAS-protein despite normal
WAS DNA and mRNA sequences, lead physicians to suspect
degradation of WAS-protein due to WIP deficiency (6). Four
years later, a large, branched family in Saudi Arabia was reported
in which four (of 12 affected) individuals with WIP deficiency
were described (7) (Table 1, pedigree B). Of these four patients,
two underwent HSCT from a matched sibling and two from
unrelated cord blood; one patient died shortly after HSCT
from CMV-mediated, respiratory distress syndrome (7). The
platelet phenotype varied inter-individually between normal-
sized ormicroplatelets andmoderate to severe thrombocytopenia
(Table 1). Similarly, skin lesions varied, but an increased risk
of infections, chronic diarrhea, and respiratory symptoms
were constantly observed. The diagnosis of these patients was
established by panel sequencing. The sixth patient was described
in a report on the effect of WIP deficiency on the actin
cytoskeleton and functional lymphocyte architecture recently
(8); and a detailed clinical description with longer follow-up of
this patient is provided below and in Table 1 (pedigree C). All
hitherto-described patients displayed an extremely early onset of
symptoms of primary immunodeficiency, but varying syndromic
and laboratory features (Table 1).
As described briefly previously, the sixth WIP-deficient
patient in this cohort (pedigree C, Table 1) became symptomatic
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TABLE 1 | Clinical synopsis of WIP deficiency.
Pedigree A Pedigree B Pedigree C
Publication (6) (7) (8)
Ethnic/geographic origin Morocco Saudi Arabia Kurdish/Turkish
Consanguinity Yes Yes Yes
Number of described
individuals/families
1 Female; another previously
deceased sibling suspected/1 family
12 Affected, 4 of whom described/1
branched family
1 Male/1 family
Centre Brescia, Italy King Faisal SHRC, Riyadh, Saudi
Arabia
Graz, Austria
Genetic aberration
Method of detection
c.1301 C>G stop-gain
Sanger sequencing after Western blot
for WASP
c.709 C>T stop-gain
whole exome & Sanger sequencing
c.373 G>A stop-gain
next generation sequencing panel & Sanger
sequencing;
+ cgh array to exclude chromosomal
aberrations
Detection of WASP Undetectable Not reported Undetectable
Gestational age,
Birth length, weight, head
circumference
No abnormalities reported No abnormalities reported Normal: 42 weeks,
49 cm (25%), 3,340 g (25–50%), 36.5 cm (75%)
Onset of symptoms (age) 11 days 1–8 weeks 4 weeks
Head and neck face, ears, eyes,
nose, mouth
Oral ulcerations on hard palate and
tongue (stopped after cord blood
transplantation [CBT])
Persistent ear infection (n = 1) Recurrent middle ear infections, large ears and
eyes, slightly downward-slanted palpebral
fissures, prominent forehead, nose, and
philtrum
Cardiovascular No abnormalities reported No abnormalities reported No abnormalities reported
Pulmonary Respiratory distress syndrome (RSV),
requiring ICU treatment, red cell and
platelet transfusions, antibiotics
CMV pneumonitis (n = 3), respiratory
infections (n = 4)
Viral bronchiolitis of unknown specificity,
CMV pneumonitis requiring ICU treatment with
long-term mechanical ventilation; obstructive
bronchitis
Abdomen Rotavirus enteritis, hepatopathy of
unknown etiology
Chronic diarrhea (n = 4); bloody
stools (n = 3); hepatosplenomegaly (n
= 1)
Inguinal hernia, recurrent bloody diarrhea,
suspected recurrent intussusception, intestinal
volvulus and near-total small bowel resection;
hepatosplenomegaly
Genitourinary No abnormalities reported No abnormalities reported No abnormalities reported
Skeletal No abnormalities reported No abnormalities reported Postnatal growth delay
Skin, nails hair Eczematous rash and papulovesicular
lesions on the scalp;
The deceased sibling was reported to
have suffered from ulcerative and
vesicular skin lesions
Scaly eczematous skin lesions
(n = 2), alopecia (n = 1)
No abnormalities reported
Neurologic No abnormalities reported No abnormalities reported Delayed development during ICU admission,
but catch-up development after clearance of
infections
Endocrine No abnormalities reported No abnormalities reported No abnormalities reported
Immunology, main features T cell lymphopenia (800 CD3/µl),
CD8+ relatively lower than CD4+,
normal TCRγ δ+ T cells,
Borderline low B cells (300/µl),
Increased NK cells (2,500/µl),
IgG, A, M normal,
IgE increased (32 IU/ml)
T cell proliferation upon PHA normal,
but reduced upon CD3 stimulation
Total T cell count normal, but mild
reduction of CD4+ T cells (in 3 of 4
patients) and severe reduction of
CD8+ T cells (n = 4),
Normal B cells,
variable NK cell number
IgG, A, M normal or increased
IgE increased (327–1,994 kU/L,
determined in 2 patients)
T cell proliferation upon PHA normal
(n = 4)
Total T cell count normal, but severe reduction
of naïve CD4+ T cells (CD4+CD45RA+
decreasing from 200 to 60/µl at 4-5 months of
age; 1.86% TREC in CD3+CD45+) and rather
increased CD8+ T cells (attributed to CMV
infection), substantially increased proportion of
TCRγδ+ T cells (>50% of CD3+; [normal
<15%]),
Normal B cells,
Normal NK cells
IgG and IgM increased, IgA normal,
IgE increased (192–1,300 IU/mL)
T cell proliferation upon PHA reduced, mildly
reduced upon ConA, low-normal upon
CD3/CD28
Other laboratory abnormalities Moderate thrombocytopenia with
normal platelet volume (average
59,000/µl platelets)
Moderate thrombocytopenia (n = 3,
75,000/µl) or severe
thrombocytopenia (n = 1, 26,000/µl)
with normal (n = 3) or reduced (n = 1)
platelet volume
Mild-moderate thrombocytopenia
(80-150,000/µl); later in course severe
thrombocytopenia (30–40,000/µl even under
romiplostim) with reduced platelet volume (≤8fl;
confirmed microscopically)
(Continued)
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TABLE 1 | Continued
Pedigree A Pedigree B Pedigree C
Other (phenotypic) features Failure to thrive,
No autoimmunity or bleeding
tendency reported
Not reported Unspecific syndromic facial dysmorphia,
No clinically manifest autoimmunity reported
Treatment CBT at 4.5 months of age; reported
at 16 months follow up clinically
healthy with complete T and B cell
donor chimerism but mixed myeloid
and NK cell chimerism.
MSD-HSCT (n = 2; one died from
CMV-RDS shortly post-transplant)
and CBT (n = 2); three surviving
patients are well 2–12 years
post-transplant
Sequential maternal HLA-identical donor
lymphocyte infusions successfully cleared CMV
and other infectious problems when clinical
condition was too bad for preparative
chemotherapy for HSCT, chronic severe
microthrombocytopenia persisted; needed IgG
supportive substitution during ICU stay but not
since DLI treatment; conditioned HSCT at 2.5
years of age was successful, restoring immune
system and platelet counts; alive and well 1
year post-HSCT.
WASP, Wiskott-Aldrich syndrome protein; CBT, cord blood transplantation; cgh, comparative genomic hybridization; RSV, respiratory syncytial virus; ICU, intensive care unit; CMV,
cytomegalovirus; TCR, T cell receptor; TREC, T cell receptor excision circles; PHA, phytohemagglutinin; ConA, concanavalin A;MSD-HSCT, matched sibling donor hematopoietic stem
cell transplantation; CMV-RDS, cytomegalovirus-mediated respiratory distress syndrome; DLI, donor lymphocyte infusions. The left and center columns summarize clinical and laboratory
findings in previously published patients(6, 7), the right columns shows data from the patient presented in this report and, in part, in Pfajfer et al. (8).
with viral bronchiolitis 4 weeks after birth, required hospital
admission and mechanical ventilation for pneumonitis at 3
months, due to a systemic CMV infection (detectable in
plasma, urine, stool, saliva, bronchial secretion, cerebrospinal
fluid) (8). Immunoglobulin-G was needed to be substituted
intravenously. Platelet concentrates were given sporadically for
intermittent bloody diarrhea with progressive thrombocytopenia
(Table 1; and Figure 1), suggesting the presence of a relapsing
intussusception, inflammatory bowel disease, or both. Endoscopy
was performed at 6 months of age and biopsies showed signs of
chronic erosive focal duodenitis (similar to infection but without
detection of CMV or Cryptosporidium), further, a chronic, active
gastritis and duodenitis (resembling reflux-association) were
found. At that time, the colon was normal, and CMV, HSV,
or other microorganisms could not be detected in situ. At 9
months of age, he had another endoscopy which showed active
duodenitis with CMV-positive stroma cells and mild colitis with
lymphoplasmacellular and patchy neutrophil infiltrations, but
no microorganisms or viruses detectable despite CMV nucleic
acid positivity in many body fluids at earlier time points. An
acute clinical deterioration was observed at 11 months of age
accompanied by clinical signs of intussusception. Emergency
surgery was performed and necrotic bowel was resected, showing
perforations, erosions, and ulcerations, as well as peritonitis.
The mucosa could not be evaluated due to necrosis, the
surgery yielded a severe short bowel syndrome. His psychomotor
development was found to be impaired, despite displaying no
signs of encephalitis (imaging; EEG; clinical) or meningitis (CSF;
imaging). However, after 25 days of invasive and 94 days of nasal
CPAP ventilation, his neurological status was difficult to assess.
The results of immunological analyses performed at 4
and 5 months of age showed clear signs of combined
immunodeficiency with reduced naïve T cells, reduced T
cell proliferation in vitro, and an increased proportion of T
cell receptor gamma-delta (TCRγδ)-positive T cells (Table 1).
Because ganciclovir treatment did not efficiently eliminate
CMV, the clinical situation was considered too unstable for a
conditioned HSCT. Since the mother was HLA-identical and
CMV-seropositive, an attempt of maternal DLI (1 × 106/kg
CD3+ T cells) was performed in his 10th month of life. Previous
reports had shown the long-term efficacy of unconditioned DLI
in the setting of a patient series with 22q11 syndrome, ZAP70
deficiency, and other syndromes (18, 19). The first DLI was
given under sirolimus to prevent the onset of graft-vs. host
disease (GvHD), the following DLIs were administered without
immunosuppression, and all were tolerated well. This led to
clinical improvement and a gradual reduction in the CMV
plasma load, with complete clearance after six doses (four DLI
at 1 × 106-1x107/kg CD3+ cells and two peripheral stem cell
concentrates at 2× 107/kg CD34+ plus 2× 107/kg CD3+ cells),
and a stable mixed T cell donor chimerism over >12 months
(>50–70% donor T cells), but expectedly did not lead to the
engraftment of myeloid cells (chimerism of CD33+ cells <2–3%
in peripheral blood) (8). Meanwhile, findings from NGS panel
diagnostics led to the diagnosis of WIP deficiency due to the
identification of a novel, stop-gain mutation inWIPF1 [c.C373T,
p.R125X; Table 1 and Pfajfer et al. (8)].
There were three indications to proceed to full conditioning
and HSCT after the elimination of CMV in this patient: (i), an
increasing frequency of ear-nose-throat (ENT) and respiratory
infections despite the predominant donor T cell chimerism and
IgG substitution; (ii), the uncertainty about the durability of the
DLI-mediated T cell engraftment; and, (iii), most urgently, the
continuous decline in thrombocyte counts (Figure 1). The latter
did not sustainably respond to thrombopoietin receptor agonists,
as treatment with eltrombopag had been attempted without effect
due to suspected malresorption in short bowel syndrome, and
even a switch to romiplostim was ineffective, although both
substances were given at standard and increased dose intensities
(Figure 1). Consequently, the patient was dependent on platelet
transfusions. Furthermore, the psychoneurological situation had
improved substantially, indicating that severe brain damage may
not have occurred. The transplantation was carried out from his
mother after conditioning with ATG-Grafalon (3 × 10mg/kg;
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FIGURE 1 | Platelet counts and therapeutic interventions in a patient with WIP deficiency. The course of platelet counts of the patient of pedigree C (Table 1, right
column) is shown as black solid line (x1,000/µl) in weeks of life (x-axis). Treatment interventions are shown in the figure legend as indicated. Doses of cell transfer and
stem cell transplantation are stated in the main text. Ptl, platelets; DLI, donor lymphocyte infusions; PBSCI, peripheral stem cell infusion (without prior conditioning
treatment); PSCT, peripheral stem cell transplantation (HSCT after conditioning pretreatment as described in the main text).
days−8,−7,−6), treosulfan (3× 12g/m2; days−5,−4,−3), and
melphalan (140mg/m2; day−2) at the age of 2.5 years, 15months
after receiving the last DLI and peripheral stem-cell infusion. The
graft contained peripheral TCRαβ/CD19-negatively selected cells
(5.7 × 107/kg CD34+ and 1.9 × 107/kg TCRγδ+CD3+ cells),
and a second fraction of CD34+ positively selected stem cells
(7.2 × 106/kg CD34+ and 2.2 × 104/kg CD3+ cells), providing
high numbers of stem cells to facilitate rapid engraftment.
GvHD prophylaxis consisted of mycophenolate mofetil (1,200
mg/m2), administered until day +46. Engraftment was excellent
with 35,000/µl leukocytes on day +8; platelet transfusion was
last required on day +9, with persisting full donor chimerism.
Ganciclovir was administered from day −10 until day +53
as a secondary prophylaxis. In addition, five doses of CMV-
specific DLI were given until day+84 in 2–4-weekly intervals
to prevent CMV reactivation. CMV nucleic acid was detectable
despite these measures in low-copy numbers (1 × 102-1.5 ×
103/mL blood) without clinical correlates until day+90, at which
point it was again negative. Apart from experiencing challenging
alimentation problems due to the short bowel syndrome and a
transient, acute, toxic pancreatitis, the patient did not experience
any severe complications. He has been progressing wonderfully,
and parenteral nutrition was gradually reduced until it was
provisionally terminated at 9 months post-HSCT. He is currently
well with>12 months follow-up after conditioned HSCT.
Because WASP undergoes proteasomal degradation,
proteasome inhibition in a condition with unimpaired WASP
synthesis could hypothetically result in intracellular stabilization
of WASP and functional restoration even in WIP deficiency.
Therefore, we performed an extensive in vitro screen with
various proteasome inhibitors, including bortezomib, with
inconclusive results. Finally, proteasome inhibition in vivo was
not attempted in any WIP deficient patient reported so far.
COMPARISON OF THE HUMAN
PHENOTYPE WITH MICE DEFICIENT IN
WIP
Newborn and young WIP null mice did not display a
pronounced phenotype, neither anatomically, developmentally,
nor hematologically, or immunologically (20, 21). However, after
8–10 weeks of life, granulocytosis and T- and B cell lymphopenia
developed, splenomegaly was noted, while platelet numbers
and volume were normal (21). A progressive lymphopenia was
noted in lymph nodes and Peyer’s plaques. Most prominently
in the clinical phenotype, mice suffered from autoimmune
inflammatory disease in many organs such as the gut, lungs,
kidneys, joints, but not skin or other organs; and antinuclear and
anti-cytoplasmatic antibodies were detected (21). The reported
differentiation block, signaling and functional alterations of
lymphocytes in WIP null mice including synapse formation and
CD19 malfunction (14, 20) associated with autoimmunity and
inflammation is similar to what was observed in humans with
WIP deficiency. However, the degree of immunodeficiency in
humans was not reflected by mice under laboratory conditions of
animal facilities, and the platelet and megakaryocyte phenotype,
which is variable in humans with WIP deficiency but rather
constantly seen in WASP deficient humans and mice (1, 22), was
not reported in WIP-deficient mice at all (21).
DISCUSSION
We provide a comprehensive synopsis of clinical and
laboratory/biological features of all hitherto-published patients
with WIP deficiency. Highly resembling WAS, subtle differences
in presentation of WIP deficiency can be observed in addition
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to the obvious difference that stems from the autosomal
recessive pattern of inheritance. The thrombocytopenia in
WIP deficiency seems to be less severe and inconstant, and
microthrombocytopenia is less frequent than in WAS, raising
the question whether other molecules could substitute for
WIP as chaperones for WASP specifically in platelets and
megakaryocytes. This might be supported by the absence of
thrombocytopenia or microplatelets in WIP deficient mice, as
reported so far. It is striking that the T-cell immunodeficiency
presents quite early in WIP deficient patients, while even classic
WAS patients often don’t present with severe opportunistic
infections before the age of one. The patient reviewed in more
detail here (the sixth of all previously published patients; from
pedigree C) displayed nearly absent naïve CD4 T-cells and
TRECs, which was not tested in the other patients, and had
reduced T cell proliferation upon stimulation with PHA, a
pathology not detected in previously tested individuals. This
and the fact that maternal T-cells were able to engraft without
conditioning may implicate a more severe T-cell deficiency than
is commonly found in WAS. On the contrary, we cannot explain
why in that patient T cell proliferation was tested low-normal
upon stimulation with CD3/CD28 in contrast to a previously
tested individual (from pedigree A). For these reasons WIP
deficiency will be more difficult to diagnose. It does suggest that
all infants with clinically severe T-cell deficiency, especially if
accompanied by thrombocytopenia, should be tested for WIP
deficiency.
Given the severe T-cell deficiency, early diagnosis of WIP
deficiency seems prudent. Certainly, newborn screening (NBS)
for TRECs would have accelerated the diagnosis in our patient
[reviewed in Kwan and Puck (23)]. However, patients with
combined immunodeficiency might not always be detected by
TREC-based NBS with cutoffs designed to detect SCID, and NBS
is not globally available. At the time of PID diagnosis, the patient
from pedigree C showed many contraindications for conditioned
HSCT, such as a systemic, invasive CMV infection, neurological
impairment, and others. Similar to previous observations (18,
19), the patient had an HLA-identical, and, in his case, CMV-
competent and WIP-proficient, family member. Despite the risk
of GvHD, the potential anti-infectious activity of peripheral
blood lymphocytes from such a donor, even with long-term
“repopulating” capacity (18, 19), was an attempt to stabilize
the clinical condition and buy time. Together, this clinical
observation (8) indicated that, also for other patients with SCID
or profound CID, an HLA-identical lymphocyte donor might be
identified, especially, in highly consanguineous pedigrees, and a
patient in a condition that is “too bad to transplant” might be
rescued by taking a DLI approach and bridging to a subsequent
HSCT.
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